In 1973, psychologist David Rosenhan published a study in Science that would shake psychiatry to its core. Eight healthy people walked into psychiatric hospitals claiming to hear voices, were diagnosed with serious mental illnesses, and despite behaving normally afterward, remained institutionalized for weeks. The experiment exposed how rigid institutional thinking could blind experts to reality itself. Half a century later, as Europe grapples with maintaining its competitive edge in global innovation, the Rosenhan experiment offers unexpected lessons about the dangers of institutional rigidity, the power of challenging assumptions, and the necessity of disruptive thinking.
The Rosenhan Experiment: A Case Study in Institutional Blindness
The beauty of Rosenhan's design lay in its simplicity. Eight pseudo-patients, including Rosenhan himself, presented at different psychiatric hospitals complaining of hearing voices that said "empty," "hollow," and "thud." Once admitted, they immediately stopped simulating symptoms and behaved entirely normally. They were cooperative, friendly, and engaged in regular activities. Yet despite this normal behavior, all were diagnosed with schizophrenia or manic-depressive psychosis and hospitalized for an average of 19 days, with some staying as long as 52 days.
The most disturbing finding wasn't just the initial misdiagnosis - it was how the psychiatric label colored every subsequent observation. When pseudo-patients took notes about their experience, staff recorded this as "patient engages in writing behavior," treating normal activities as symptoms. One patient's biographical details, describing a close relationship with his mother as a child but a more distant one as an adult, was interpreted through the lens of pathology as evidence of "ambivalent relationships." Ironically, actual patients often recognized the pseudo-patients as imposters, but the medical professionals never did.
The Rosenhan experiment was itself a profound act of innovation - not in creating something new, but in exposing what was fundamentally broken. Rosenhan didn't develop a new treatment or theory; he challenged the very foundations of how psychiatric diagnosis operated. This mirrors what true innovation does in any field: it questions assumptions so deeply embedded that they've become invisible.
Europe's innovation landscape today faces a similar challenge. The continent that gave birth to the Industrial Revolution, produced countless scientific breakthroughs, and built world-leading educational institutions now finds itself trailing in key innovation metrics. China filed 1.8 million patent applications in 2024. The United States filed 501,831. Germany, Europe's leader, managed only 133,485. Asia now accounts for 70.1% of global patent applications, while Europe's share has fallen to just 9.7%. In AI patents specifically, all European countries combined received only 1,173 grants in 2022, a mere 2% of the global total, compared to China's 61% and America's 21%.
The unicorn statistics are equally brutal. The United States hosts 656 billion-dollar startups, China has 168. The entire United Kingdo, Europe's leading tech hub, has 53. Germany has 30. France has 26. Together, the US and China account for 77% of the world's unicorns.
Why? Like the psychiatric hospitals in Rosenhan's study, European innovation ecosystems suffer from institutional rigidity. Regulatory frameworks designed for industrial-age economies struggle to accommodate platform businesses and digital services. Labor laws that protect workers make it difficult for startups to scale quickly. Risk-averse banking systems and capital markets force European entrepreneurs to flee to the US for venture funding. Educational institutions, while prestigious, are slow to adapt curricula to rapidly changing technological landscapes.
Consider the fate of Danish fintech startup Tradeshift. Despite building a successful procurement platform in Copenhagen, the company relocated its headquarters to Silicon Valley to access American clients and funding, the only viable path to unicorn status. Or take TransferWise (now Wise), which nearly moved from London to New York before Brexit, stopped only by the founders' stubborn attachment to Europe. These aren't isolated incidents. They're symptoms of a system that makes entrepreneurs choose between staying European or staying competitive.
The parallel is striking: just as psychiatric hospitals couldn't see sanity when their diagnostic framework predisposed them to see illness, European institutions struggle to recognize and nurture genuinely disruptive innovation when it conflicts with established regulatory, cultural, or economic structures.
The Power of Questioning Assumptions
What made Rosenhan's experiment so powerful was his willingness to question a fundamental assumption: that psychiatric professionals could reliably distinguish the sane from the insane. This wasn't meant to mock psychiatrists but to expose how context, expectations, and institutional frameworks shape perception.
Europe's most successful innovators have similarly questioned assumptions that others took for granted. Spotify challenged the assumption that people would always prefer to own music rather than access it. BioNTech questioned whether traditional vaccine development timelines were truly necessary, helping deliver a COVID-19 vaccine in record time. Arm Holdings reimagined what a semiconductor company could be by focusing on licensing intellectual property rather than manufacturing chips.
These European success stories share something with Rosenhan's approach: they identified an assumption that everyone else accepted, questioned whether it was actually true, and built something new from that insight. They demonstrate that Europe possesses the capability for world-changing innovation. The question is whether European ecosystems systematically encourage or discourage this kind of fundamental questioning.
In Rosenhan's hospitals, questioning diagnoses was itself seen as symptomatic - a catch-22 where asserting your sanity proved your insanity. European innovators face similar paradoxes. Regulatory compliance requires following established rules, but breakthrough innovation often means operating in spaces where clear rules don't yet exist. Accessing EU research funding requires fitting into predefined categories and demonstrating measurable outcomes, yet the most transformative innovations are often those whose impact couldn't have been predicted in advance.
Perhaps the most chilling aspect of the Rosenhan experiment was the stickiness of psychiatric labels. Once diagnosed with schizophrenia, the pseudo-patients found that label colored every interaction, every observation, every interpretation of their behavior. Even upon discharge, they weren't declared "healthy" but rather "in remission”, a label that suggested the illness was merely dormant, not absent.
Europe faces its own version of sticky labels. Many European economies are still labeled as "Old World," contrasted with the dynamism of the "New World" or emerging markets. Certain sectors, automotive, aerospace, pharmaceuticals - are seen as European strengths, while tech and digital services are assumed to be American or Asian domains. These labels, like psychiatric diagnoses, create self-fulfilling prophecies. If European policymakers, investors, and entrepreneurs believe Europe is naturally better suited for traditional industries, that's where resources flow.
The challenge is compounded by Europe's genuine strengths becoming burdens. Strong worker protections make it harder to embrace the "fail fast" startup culture. Strong privacy regulations like GDPR protect citizens but slow down AI development that relies on large datasets. Excellence in manufacturing creates path dependencies that make it harder to pivot toward platform businesses. Like a pseudo-patient whose every action is interpreted through their diagnosis, European innovations are evaluated through frameworks designed for a different economic era.
Barriers to Innovation: Institutional Structures That Resist Change
The psychiatric hospitals in Rosenhan's study weren't filled with incompetent or malicious people. They were staffed by trained professionals operating within established protocols and institutional structures. The problem wasn't individual failure but systemic rigidity - structures that made it nearly impossible to correct initial errors or recognize evidence that contradicted prevailing assumptions.
European innovation faces similar structural barriers. The continent's fragmentation into different regulatory regimes means a startup that succeeds in one country faces new hurdles in each additional market. A European tech company must navigate different languages, regulations, tax systems, and cultural preferences across a shorter geographic distance than an American company operating coast to coast. Compare this to the United States' single market or China's massive unified domestic market, and the disadvantage becomes clear.
Capital structures also create barriers. European pension funds and institutional investors prefer stable returns over high-risk, high-reward investments. This creates a venture capital gap that forces European entrepreneurs to seek American funding, often requiring them to relocate or restructure their companies to satisfy US investors' expectations. The result is a brain drain where Europe's most promising innovations end up benefiting other economies. European unicorns typically require an average of 9.9 investors to reach billion-dollar valuations, compared to 7.3 for US unicorns and just 5.3 for Chinese ones - a symptom of fragmented capital markets and risk aversion.
Educational and research institutions, despite their prestige, can also be institutionally rigid. The gap between academic research and commercial application, the so-called "valley of death”, is often wider in Europe than in the US, where universities like Stanford and MIT have systematically developed pathways for research commercialization. European researchers publish outstanding papers but struggle to turn discoveries into companies.
If the Rosenhan experiment teaches us anything, it's that exposing problems is the first step toward solving them. Rosenhan's study led to significant reforms in psychiatric diagnosis, including more rigorous diagnostic criteria and greater attention to the social context of behavior. Similarly, recognizing the structural barriers to European innovation creates opportunities for reform.
Some promising developments suggest Europe is learning these lessons. The European Innovation Council, established in 2021, aims to identify and support high-risk, high-reward innovations. Initiatives like the Capital Markets Union seek to create more integrated European capital markets. Digital Services Act and Digital Markets Act represent attempts to regulate tech platforms in ways that protect consumers while potentially creating opportunities for European competitors.
Individual countries are also experimenting with approaches that question old assumptions. Estonia's digital-first governance model demonstrates that small countries can lead in innovation. France's Station F, one of the world's largest startup campuses, shows Europe can create spaces for entrepreneurial culture to flourish. Germany's Mittelstand companies, small and medium enterprises that are world leaders in niche markets - demonstrate that innovation doesn't require Silicon Valley's model of winner-take-all platforms.
Europe must adopt the mindset that made the Rosenhan experiment so powerful: a willingness to question fundamental assumptions, even, especially, when those assumptions are held by experts and embedded in institutional structures. Europe needs its own Rosenhans, willing to conduct "experiments" that expose where established thinking has become divorced from reality.
Conclusion: The Courage to Question
The Rosenhan experiment succeeded because it had the courage to question what everyone else accepted. It revealed that the emperor had no clothes, that the supposedly objective science of psychiatric diagnosis was profoundly influenced by context, expectation, and institutional inertia. The experiment itself was an act of innovation, not creating something new, but seeing clearly what was already there.
Europe's innovation challenge requires similar courage. The continent must question assumptions about risk, failure, regulation, and what kinds of economic activity are appropriate for European societies. It must recognize where institutional structures designed for past challenges have become barriers to future opportunities. And it must create space for genuinely disruptive innovations, even when they challenge established interests and comfortable certainties.
The pseudo-patients in Rosenhan's hospitals were eventually released, though it took far longer than it should have. Europe has what it takes to be a global innovation leader, proven by every successful European startup that questions the rules rather than accepting them. The question is whether the continent can break free from the institutional structures that, like diagnostic labels, shape how opportunities are perceived and pursued. In both cases, the solution begins with the simple but radical act of questioning what everyone else assumes to be true.
Footnote: In recent years (notably in Susannah Cahalan's book The Great Pretender), evidence has emerged suggesting Rosenhan may have manipulated or even fabricated parts of the data. While the scientific rigor of the original study is now heavily questioned, I have chosen to use this story because the lesson it illustrates, how institutional frameworks shape perception and how rigidity blinds systems to contrary evidence, remains valid regardless of whether every detail of Rosenhan's account was accurate. The conceptual point stands: institutions can become trapped by their own diagnostic frameworks, whether in psychiatry or innovation policy.